In February, Johnson & Johnson Innovation, JLABS opened its first European open innovation incubator, JLABs @ BE, at the heart of the Beerse Janssen R&D Campus in Belgium. European Biotechnology spoke with Günter Huhle, Head of Johnson & Johnson Innovation JLABS EMEA, about Johnson & Johnson‘s approach to open innovation and its tremendous global innovation network, currently comprising ten incubators and over 420 companies that have collectively raised over US$10bn in growth capital.
Epigenetic drugs can increase tumour malignancy
Latest NewsResearchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.
A unique approach to bring open innovation to Europe
OpinionIn February, Johnson & Johnson Innovation, JLABS opened its first European open innovation incubator, JLABs @ BE, at the heart of the Beerse Janssen R&D Campus in Belgium. European Biotechnology spoke with Günter Huhle, Head of Johnson & Johnson Innovation JLABS EMEA, about Johnson & Johnson‘s approach to open innovation and its tremendous global innovation network, currently comprising ten incubators and over 420 companies that have collectively raised over US$10bn in growth capital.
Forbion leads €40m financing in Inflazome Ltd
Latest NewsInflammosome inhibitor specialist Inflazome Ltd has raised €40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners.
EC advisors call for update of GM legislation
Latest NewsThe EU Commission’s Chief Scientific Advisors urge the Commission to revise the EU’s GMO Directive in order to harness gene editing.
Eppendorf BioFlo® 120 Bioprocess Control Station
ProductsThe flexible BioFlo 120 bioreactor/fermentor control station is capable of microbial fermentation as well as mammalian cell culture applications.
Boehringer and Epizyme enter US$300m deal
Latest NewsBoehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.
Breakthrough in restless legs syndrome
Latest NewsResearchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome.
Hox Therapeutics appoints Karl Keegan as CEO
AppointmentsHox Therapeutics has announced the appointment of Dr Karl Keegan as Chief Executive Officer.
SOBI and AstraZeneca in US$2bn+ deal on RSV antibodies
Latest NewsAstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish Orphan Biovitrum AB.
Amal bags €21.2m financing
Latest NewsSwiss Amal Therapeutics S.A. (Geneva) has raised €21.2m in a series B follow-up financing.